News

In a climate of shrinking reimbursements and rising costs, finding your niche isn’t just smart—it’s essential.

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.

Rachelle Lin, OD, MS, FAAO, has refined her passions for academia, teaching, low vision practice, and advocacy work to build out a well-rounded career.

Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

TearCare is associated with greater health utility over time but also resulted in significant cost savings compared with CsA.

Specialty care is always needed in any field, and myopia control is no exception.

With FDA approval of LENZ Therapeutics’ Vizz (LNZ100), optometrists now have a daily, non-invasive treatment option for presbyopia, giving patients more freedom and clinicians greater flexibility in care.

The planned acquisition of STAAR includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia with or without astigmatism.

Diagnostic tools, therapeutic innovations such as anti-vascular endothelial growth factor (VEGF) therapies, and supportive technologies to manage vision loss form the myopic macular degeneration market.

Better best-corrected visual acuity values and baseline thicker ganglion cell layer and retinal nerve fiber layer at ocular coherence tomography measurements were found to be the key predictive factors.

The partnership marks a major step toward expanding global access to targeted treatments for this vision-threatening condition, according to a news release.

Due to ubiquity, optometrists tend to undertreat patients with dry eye.

Catch up on the top stories in optometry during the week of July 28-August 1.

The latest in drug and technology developments and updates from July 2025.

Additionally, the company is exploring different strategic alternative to advance its suprachoroidal space (SCS) platform and drug development pipeline.

The solution was approved by the US Food and Drug Administration in late May 2025.

The new facility has opened just in time to see its first classes held in the fall semester.

Vizz (LENZ Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution to correct vision for up to 10 hours.

In this podcast, Marjan Farid, MD; Beeran Meghpara, MD; and John Hovanesian, MD; review the role of neuromodulation in the pathogenesis of dry eye disease (DED). Additionally, the expert panel discusses a case study of a typical patient presenting with DED and reviews current and newly available treatment options.

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

The expanded clinical suite at Stanton Optical will include keratography, optical coherence tomography, and personalized therapy options for patients with dry eye.

Paul Levine, OD, FAAO, FIAOMC, details a pediatric case of high myopia in which the patient's prescription had increased from –5.75 DS OU to OD –7.00 DS, OS –6.75 DS within a year.

The first-in-class, twice-daily topical formulation is intended for the treatment of nonproliferative diabetic retinopathy and diabetic macular edema.

A total of $7000 in scholarships was awarded to 3 optometry students as part of the National Optometric Student Association (NOSA) scholarship program.

The study's primary objective was to demonstrate that LUMIFY Preservative Free redness reliever eye drops are noninferior to LUMIFY redness reliever eye drops in reducing ocular redness.

The module can be used in combination with Ziemer’s FEMTO LDV Z8 femtosecond laser platform, an all-in-one laser for refractive, cataract, and therapeutic surgery.

Gyrate atrophy of the choroid and retina is a form of choroidal sclerosis and is a rare, progressive, autosomal recessive, inherited genetic disease that primarily affects the ocular tissue.